



## **THERMOGENESIS PRESENTED AT FT GLOBAL PHARMACEUTICALS AND BIOTECHNOLOGY CONFERENCE**

### ***Philip Coelho Participates in Panel About Enhancing Value Through Medical Technology***

**RANCHO CORDOVA, CA, SEPTEMBER 18, 2006** –ThermoGenesis Corp. (Nasdaq: KOOL) announced today that Philip H. Coelho, the Company’s Chairman and Chief Executive Officer, participated in the *Financial Times*’ Global Pharmaceuticals and Biotechnology Conference which took place September 18th and 19th, 2006 at the Dorchester in London.

Mr. Coelho presented on a panel entitled “Medical Technology – Enhancing Value” along with representatives from GE Healthcare and Oracle Corp. The *Financial Times*’ pharmaceutical correspondent chaired the panel.

“I was honored to participate at this prestigious international health care industry conference alongside leading medical technology experts,” Mr. Coelho said. “The conference offers a forum to discuss and discover common solutions to the worldwide challenges and opportunities facing the biotech and pharmaceutical industries. As a company that has signed agreements for its cell therapy and wound care products and technologies with various companies, including GE Healthcare and Biomet, we are proud to be part of that dialogue.”

The presentation will be available for a limited time on the Company’s web site at [http://www.thermogenesis.com/investor\\_relations/index.asp](http://www.thermogenesis.com/investor_relations/index.asp) beginning September 19, 2006.

### **About ThermoGenesis Corp.**

ThermoGenesis Corp. ([www.thermogenesis.com](http://www.thermogenesis.com)) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

- **The BioArchive® System**, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant. GE Healthcare is the non-exclusive global distribution partner for the BioArchive System.
- **The AutoXpress System™ (AXP™)**, is a newly-developed semi-automated device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood. GE Healthcare is the exclusive global distribution partner for the AXP AutoXpress System.
- **The CryoSeal® FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. Enrollment in a 150-patient U.S. pivotal clinical trial has been completed and a PMA is being reviewed by the FDA. The CryoSeal FS System has received

the CE-Mark. From a marketing perspective, the CE Mark is the European equivalent to an FDA approval, in that it allows sales of the product throughout the European community.

- **The Thrombin Processing Device™ (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2007, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2007. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

**ThermoGenesis Corp.**

Web site: <http://www.ThermoGenesis.com>

Contact: Fern Lazar of Lazar Partners

+1-212-867-1762